Business Standard

Covid-19 vaccination: Serum Institute to gain from G7's boost to COVAX

The immediate contribution will be $2 billion. More than 180 nations are yet to administer a single dose of the Covid vaccine

New Delhi: The first batch of Covishield vaccine reaches central storage facility at Rajiv Gandhi Super Specialty hospital in New Delhi, Tuesday, Jan. 12, 2021. (PTI Photo/ Kamal Kishore)
Premium

PTI Photo/ Kamal Kishore

Ashis Ray London
Serum Institute of India (SII), which has the world’s biggest vaccine production facility, could be a major beneficiary of the G7’s decision to enhance funding to finance coronavirus vaccine supply to low- and middle-income countries.
 
India, dubbed the “pharmacy of the world”, furnishes 60 per cent of the world’s vaccines across a variety of diseases. That should compensate for any dwindling in demand in India, amid reports the immunisation effort has stumbled, because of a fall in infections and lack of confidence in a vaccine candidate approved before completing phase three trials.
 
Smisha Agarwal, a research director at

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 19 2021 | 11:08 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com